Clinical Trials in China / NCT07186088
Enrolling by invitation
Not applicable
Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies
NCT07186088 · tracked via the Priya Life Science China tracker
Condition(s) studied
Myopia
Investigational drug(s) / intervention(s)
Eyerising RS-200-2AEyerising SLX-1A
Eyerising RS-200-2A: Eyerising RS-200-2A,1 time,2 times, 3 times a day
Eyerising SLX-1A: Eyerising SLX-1A, 2 times a day
Study summary
To explore the effectiveness and safety of repeated exposure to repeated low-intensity red light
Eligibility
Inclusion Criteria:
* 18-35 years old, gender not limited; Obtained informed consent.
Exclusion Criteria:
* Obvious strabismus and amblyopia
* With congenital eye disease, such as congenital cataract, congenital retinal disease
* Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)
* Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)
* Refractive medium opacity (such as corneal disease, crystal opacity, etc.)
* Bnormal intraocular pressure and clinical significance (IOP \<10 mmHg or IOP\>21mmHg or binocular IOP difference ≥5mmHg)
* Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases
* Optic nerve damage or congenital optic nerve dysfunction
* Can not be regularly checked
* The adjustment range is less than 8D or obvious near difficulties
* Other reasons researchers think it is not suitable for inclusion in researchers
Primary outcome measure(s)
- Axial length — From enrollment to the end of treatment up to 7 months
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Tianjin Medical University Eye Hospital | Tianjin | Tianjin Municipality |
More Ruihua Wei trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07186088 on ClinicalTrials.gov ↗ ← All trials in China